2023 年 18 巻 1 号 p. 27-33
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of novel coronavirus disease 2019 (COVID-19), a major cause of atypical pneumonia worldwide. Elderly individuals and those with underlying illnesses, such as cardiovascular and pulmonary diseases, are at a high risk of experiencing severe symptoms and have high mortality rates. There is therefore a major need to develop additional vaccines, effective treatments, and complementary drugs to control this infection. Lactoferrin (LF), a naturally-occurring glycoprotein, is bioactive against viruses and other pathogens. LF has a unique immunomodulatory function and is indispensable for immunity in infants. It is thought to contribute to biological defense in individuals across all generations, not only infants. LF inhibits viral adhesion to host cell surfaces through ionic binding to glycosaminoglycans and/or specific binding to viral structures. Purified LF is cost-effective and orally available as a dietary supplement. Here, we review studies on the protective role of LF against common viral infections. Based on this review, we propose that LF can be a possible prophylactic or therapeutic agent for COVID-19 disease.
この記事は最新の被引用情報を取得できません。
